Betacam Polypeptide for Non-Invasive Beta Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a non-invasive and unbiased means to assess pancreatic beta cell mass and activity in humans, hindering diagnosis and monitoring of diabetes, particularly in type I and type II diabetes, and islet transplantation efficacy.
Innovation Solution
The discovery and utilization of the Betacam polypeptide, selectively expressed on pancreatic islet cells, allows for the development of compositions and methods to detect and isolate beta cells, and modulate their activity, enabling improved diagnosis and treatment of diabetes through non-invasive detection and purification techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If biopsy analysis followed by histological assessment is used to measure beta cell mass, then measurement accuracy is improved, but invasiveness increases and non-invasive assessment becomes impossible
Solution Approach 1:
The patent replaces mechanical/biopsy-based assessment with non-invasive imaging technology. Specifically, it uses MRI or PET imaging with radiolabeled compounds that bind to beta cells, allowing visualization and quantification of beta cell mass without tissue sampling. This substitutes the mechanical biopsy procedure with a non-invasive imaging system while maintaining measurement capability.
Solution Approach 2:
The patent introduces radiolabeled compounds or antibodies as intermediaries that specifically bind to beta cells. These intermediaries serve as mediators between the imaging system and beta cells, allowing indirect detection and quantification of beta cell mass through the signal emitted by the radiolabeled compounds, thus avoiding direct tissue invasion.
2Object-affected harmful factors
If radiolabeled compounds are used for non-invasive beta cell detection, then non-invasive assessment is enabled, but measurement precision and specificity may be reduced
Solution Approach 1:
The patent applies local quality by using radiolabeled compounds or antibodies that specifically target and bind only to beta cells, not other cell types. This specificity ensures that the signal detected comes exclusively from beta cells, maintaining measurement precision despite the non-invasive approach. The local quality of specific binding distinguishes beta cells from surrounding tissue.
Solution Approach 2:
The patent utilizes radiolabeled compounds that emit detectable signals (analogous to color changes in optical detection) when bound to beta cells. The radiolabels emit radiation or signals that can be detected by imaging systems, providing a clear distinction between beta cells and other tissues, thereby maintaining measurement precision through signal differentiation.
3Reliability
If multiple transplants are required for islet transplantation, then treatment reliability improves, but treatment complexity and time increase
Solution Approach 1:
The patent implements feedback by enabling non-invasive monitoring of beta cell mass and function after transplantation using radiolabeled imaging. This allows real-time assessment of graft viability and engraftment success, providing feedback to clinicians about whether additional transplants are truly necessary. The imaging capability gives direct visualization of the transplanted islets' status, reducing the need for empirical multiple transplants.
Data Source
AI summary
The invention is based, in part, on the discovery that a polypeptide, referred to herein as Betacam, is selectively expressed on the surface of pancreatic islet cells. Thus, in one aspect, the invention is directed to compositions comprising Betacam or that can be used to detect Betacam. In another aspect, the invention provides methods of detecting (e.g., non-invasively) pancreatic beta cells from a mammalian cell source. Another aspect of the invention is directed to cellular purification of pancreatic beta cells from a heterogeneous cell source of multiple kinds. In another aspect, the invention provides methods of identifying agents that modulate activity of Betacam. In yet another aspect, the invention provides for improved treatment and diagnosis of diabetes.